Aleva Neurotherapeutics SA Revenue and Competitors
Estimated Revenue & Valuation
- Aleva Neurotherapeutics SA's estimated annual revenue is currently $4.5M per year.
- Aleva Neurotherapeutics SA's estimated revenue per employee is $251,000
Employee Data
- Aleva Neurotherapeutics SA has 18 Employees.
- Aleva Neurotherapeutics SA grew their employee count by -44% last year.
Aleva Neurotherapeutics SA Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is Aleva Neurotherapeutics SA?
Aleva Neurotherapeutics SA, a company located at the Innovation Park of the Swiss Federal Institute of Technology (EPFL) in Lausanne, is active in development of innovative active implantable devices for Deep Brain Simulation for the treatment of Parkinson's Disease.
keywords:N/A
N/A
Total Funding
18
Number of Employees
$4.5M
Revenue (est)
-44%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Aleva Neurotherapeutics SA News
Jude Medical, Inc., LivaNova PLC, Boston Scientific Corporation, Aleva Neurotherapeutics SA, BioControl Medical, Bioness Inc., EnteroMedics Inc, Nevro...
... Boston Scientific Corporation, NeuroPace Inc, BioControl Medical, Bioness Inc., Nevro Corporation, Aleva Neurotherapeutics SA.
... Synapse Biomedical Inc.; ReShape Lifesciences, Inc.; Bioness Inc.; Aleva Neurotherapeutics SA; LivaNova PLC; Neuronetics; Cyberonics,...
Other Companies in Lausanne
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.5M | 18 | -14% | N/A |
#2 | $2.4M | 18 | -10% | N/A |
#3 | $4.5M | 18 | -31% | N/A |
#4 | $1.5M | 18 | 20% | N/A |
#5 | $1.5M | 19 | 27% | N/A |